Adherence to immunomodulatory drugs in patients with multiple myeloma.
Fiche publication
Date publication
janvier 2019
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis, Dr CHRETIEN Marie-Lorraine
Tous les auteurs :
Cransac A, Aho S, Chretien ML, Giroud M, Caillot D, Boulin M
Lien Pubmed
Résumé
Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients.
Référence
PLoS ONE. 2019 ;14(3):e0214446